The ongoing battle against cancer has seen significant advancements over the years, yet one of the most daunting challenges remains: the recurrence of tumors. Despite the development of new treatments, many patients experience a return of their cancer, often more aggressive than before. This persistent issue underscores the need for innovative solutions that not only treat cancer but also prevent it from coming back.

Farmington, CT, December 14, 2023– CaroGen Corporation, a developer of transformative immunotherapies for cancer and infectious diseases, announced today that preclinical data on CARG-2020, its flagship immuno-oncology clinical candidate for ovarian cancer, has been published in the Journal of Cancer Immunology Research (Alvero et al. Cancer Immunol Res (Dec. 2023, in press)).

Farmington, CT, September 20, 2023 – CaroGen Corporation, a developer of transformative immunotherapies for cancer and infectious diseases, announced today that preclinical data on CARG-2020, its flagship immuno-oncology candidate for solid tumors, has been published in the Journal of Acta Pharmaceutica Sinica B (https://doi.org/10.1016/j.apsb.2023.08.034).

Ayesha Alvero, MD, MSc, professor, Department of Obstetrics and Gynecology, Wayne State University School of Medicine, discusses findings from a preclinical study investigating the antitumor effects and recurrence prevention abilities of a virus-like vesicle thought to establish immunological memory in mouse models with ovarian cancer.

At the 2023 Society of Gynecological Oncology’s Annual Meeting on Women’s Cancer in Tampa, Florida, Ayesha Alvero, MD, C.S. Mott Center at Wayne State University, Detroit, Michigan, discusses the use of the novel immunomodulatory virus CARG-2020 to restore immunosurveillance and establish anti-tumoral immunological memory to prevent ovarian cancer recurrence.

Farmington, CT, November 8, 2022 – CaroGen Corporation (https://carogencorp.com), a developer of transformative immunotherapies for cancer and infectious diseases, today announced that new preclinical data about the mechanism of action of CaroGen’s novel ovarian cancer immunotherapy, CARG-2020,

Farmington, CT, September 5, 2022– CaroGen Corporation (https://carogencorp.com), a developer of transformative immunotherapies for cancer and infectious diseases, today announced that Bijan Almassian, PhD, President & CEO,

We are honored to be working with NIAID/NIH scientists to develop a universal influenza vaccine.

Striving to develop CARG-201 as a novel immunotherapy for potential functional cure of over 250 million patients worldwide chronically infected with hepatitis B virus (HBV). Currently there is no cure for HBV.

Farmington, Conn., Oct. 25, 2020 – Privately-held CaroGen Corp., in collaboration with a team of scientists at the C.S. Mott Center for Human Growth and Development at Wayne State University..

UConn Health researchers, along with industry partners, have developed a promising potential candidate for treating colorectal cancer.

Great to have an interview with Louis Garguilo, Chief Editor, Outsourced Pharma regarding to one of our lead products, CARG-201 for potential functional cure of patients chronically infected with HBV.

Very honored to be selected by Hartford Business Journal as one of top 25 technology companies in state of Connecticut. We develop breakthrough immunotherapies and vaccines for cancer and infectious diseases.

Bijan Almassian : Striving To Build Super Vaccines and Immunotherapies While the coronavirus has caused havoc throughout the globe. Another such disease that has haunted humanity for years is cancer. Throughout the years, many cancer researchers have…

It is humbling to be recognized by Healthcare Insight magazine as 10 most advanced biotech startups of 2021.

We are grateful for receiving such a significant grant by Department of Defense to advance our HBV immunotherapy into clinic.